Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).

Journal Article (Journal Article)

Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of care adjuvant platinum-based chemotherapy. Clinical trial registration: NCT04267848 (

Full Text

Duke Authors

Cited Authors

  • Sands, JM; Mandrekar, SJ; Kozono, D; Oxnard, GR; Hillman, SL; Wigle, DA; Govindan, R; Carlisle, J; Gray, J; Salama, JK; Raez, L; Ganti, A; Foster, N; Malik, S; Bradley, J; Kelly, K; Ramalingam, SS; Stinchcombe, TE

Published Date

  • June 2021

Published In

Volume / Issue

  • 13 / 9

Start / End Page

  • 727 - 734

PubMed ID

  • 33878954

Pubmed Central ID

  • PMC8293026

Electronic International Standard Serial Number (EISSN)

  • 1750-7448

Digital Object Identifier (DOI)

  • 10.2217/imt-2021-0019


  • eng

Conference Location

  • England